A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-217 in the Treatment of Adult Female Subjects With Severe Postpartum Depression
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2018
At a glance
- Drugs SAGE 217 (Primary)
- Indications Postnatal depression
- Focus Therapeutic Use
- Sponsors Sage Therapeutics
- 29 Mar 2018 Planned number of patients changed from 60 to 140.
- 29 Mar 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 29 Mar 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.